Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot

Shattuck Labs (STTK) pivots from oncology to focus on SL-325 for inflammatory bowel disorders, following underwhelming ...
Nasdaq

Erasca, Inc. Reports Promising Preclinical Data on ERAS-0015 and ERAS-4001 Targeting RAS/MAPK Pathway at AACR Annual Meeting

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...

BRC Therapeutics Announces Peer-Reviewed Publication on Navigating Drug Development Pathways for Botanical Cannabinoid Medicines

BRC Therapeutics (BRC), a pharmaceutical company developing proprietary therapeutics for neurological and inflammatory diseases, tod ...

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...
AZoLifeSciences on MSN

Blocking retinoic acid pathway improves dendritic cell anti-tumor function

Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by ...